Activating mutations in the KRAS oncogene and inactivation of the TP53 tumor suppressor gene are the most common genetic abnormalities identified in human lung adenocarcinoma, occurring in ~30% and 50% of the patients, respectively [6]. This evidence concerns the gene TP53 and lung adenocarcinoma.